1. Highlights From the 2017 Annual European MS Meeting

2. This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. The program will also include a discussion of off-label treatment not approved by the FDA for use in the U.S.

4. Investigational Disease-Modifying Therapies for MS

5. Long-Term Lymphocyte Counts in Patients With RRMS Treated With Cladribine Tablets, 3.5 mg/kg

6. Cladribine: Background

7. Long-Term Lymphocyte Counts and Cladribine

8. Long-Term Lymphocyte Counts and Cladribine: Results

9. Radiologic Outcomes of Cladribine in Patients With MS and HAD: Background

10. Radiologic Outcomes of Cladribine in Patients with MS and HAD: Post Hoc Analysis

11. Radiologic Outcomes of Cladribine in Patients with MS and HAD: Results

12. Concluding Remarks

13. Biomarkers for Prognostication in Early MS

14. Purpose of Biomarkers in MS

15. Neurofilaments

16. NfL Concentrations and CIS Objectives and Methods

17. NfL Concentrations and CIS Results

18. NfL Concentrations and CIS Conclusions

19. Intrathecal Ig in MS Background

20. Intrathecal Ig in MS Aim and Study Design

21. Intrathecal Ig in MS Results

22. Overall Conclusions

23. What Is New in Progressive Forms of MS?

24. Risk of SPMS Methods

25. Risk of SPMS Results

26. Predicting MS Disease Progression From Placebo Arms

27. Predicting MS Disease Progression From Placebo Arms Statistical Methods, Definitions, and Baseline Factors

28. Predicting MS Disease Progression From Placebo Arms Results

29. PPMS Misdiagnosis in Europe and US Background

30. PPMS Misdiagnosis in Europe and US Methods

31. PPMS Misdiagnosis in 5EU and U.S. Results

32. PPMS Misdiagnosis in 5EU and US Conclusions

33. Brain Reserve and Cognitive Reserve in Progressive MS Methods

34. Brain Reserve and Cognitive Reserve in Progressive MS Results

35. Exposure to DMTs Among Pregnant Women With MS

36. Background

37. Pregnancy Incidence and Therapy Exposure in MS Methods

38. Pregnancy Incidence and Therapy Exposure in MS Results

39. Pregnancy Outcomes With Alemtuzumab Background

40. Pregnancy Outcomes With Alemtuzumab Results

41. Pregnancy Outcomes With Cladribine Background

42. Pregnancy Outcomes With Cladribine Results

43. Conclusions

44. Abbreviations

45. Abbreviations (cont)